Industry News
Identifying Glioblastoma Patients Most Likely To Benefit From Bevacizumab
Jun 04, 2013
A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®), according to new research from The University of Texas MD Anderson Cancer Center. The results of the study were presented at the annual meeting of the American Society of Clinical Oncology... Read More
No Benefit Offered By Bevacizumab For Newly Diagnosed Glioblastoma
Jun 04, 2013
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center... Read More
Symptoms Of Burnout Suffered By Many US Oncologists Despite High Career Satisfaction
Jun 04, 2013
Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology's annual meeting in Chicago... Read More
Sorafenib Stops Tumor Growth And Provides The First Effective Treatment For Thyroid Cancer Patients Who Progress Following Standard Therapies
Jun 04, 2013
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which was presented by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncolo... Read More
We Need More Breast Cancer Trials For Younger Patients Urge Experts
Jun 03, 2013
The poorer survival rates of younger breast cancer patients could be a result of insufficient clinical trials for this age group. This was a conclusion of a major new Cancer Research UK study published online recently in the Journal of the National Cancer Institute (JNCI)... Read More
New Anticancer Drug Shows Effect Against Melanoma
Jun 03, 2013
A new drug being tested in patients with advanced melanoma, the most dangerous form of skin cancer, has shown significant antitumor activity, according to preliminary results of a new study. The research, conducted by a team of experts from UCLA's Jonsson Comprehensive Cancer Center, led by Dr... Read More
Avastin Can Lengthen The Lives Of Advanced Cervical Cancer Patients
Jun 03, 2013
The addition of targeted therapy Avastin (bevacizumab) with chemotherapy can significantly lengthen the lives of women with advanced cervical cancer by close to 30%, according to research presented at the 2013 American Society of Clinical Oncology Congress. The finding is an important discovery in the fight against cervical cancer - the most common cancer in women under the age of 35... Read More
10 Years On Tamoxifen Halves Breast Cancer Recurrence Risk
Jun 03, 2013
Survivors who take tamoxifen for ten years have half the risk of dying from estrogen receptor positive breast cancer, researchers from Cancer Research UK reported at the ASCO Annual Meeting in Chicago, Illinois, USA... Read More
HER2 Abnormalities Found In Many Advanced Cancers
Jun 03, 2013
We already know that an over-active HER2 growth factor gene features in breast and gastric cancers. Now a new study reports finding mutations and other abnormalities of the gene in 14 different advanced cancers... Read More
Sorafenib (Nexavar) Delays Rare Thyroid Cancer By 5 Months
Jun 03, 2013
Sorafenib (Nexavar) stops metastatic thyroid cancer tumor growth for nearly twice as long as a placebo, researchers from Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania announced as they reported on a randomized phase III trial at the ASCO Annual Meeting in Chicago, Illinois... Read More
Previous Page Next Page